Cancer Research UK Drug Discovery Unit, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom.
Acta Crystallogr D Struct Biol. 2022 Nov 1;78(Pt 11):1294-1302. doi: 10.1107/S2059798322009986. Epub 2022 Oct 27.
Crystallographic fragment screens provide an efficient and effective way to identify small-molecule ligands of a crystallized protein. Due to their low molecular weight, such hits tend to have low, often unquantifiable, affinity for their target, complicating the twin challenges of validating the hits as authentic solution-phase ligands of the target and identifying the best' hit(s) for further elaboration. In this article, approaches that address these challenges are assessed. Using retrospective analysis of a recent ATAD2 hit-identification campaign, alongside other examples of successful fragment-screening campaigns, it is suggested that hit validation and prioritization are best achieved by a
triangulation' approach in which the results of multiple available biochemical and biophysical techniques are correlated to develop qualitative structure-activity relationships (SARs). Such qualitative SARs may indeed be the only means by which to navigate a project through the tunnel of uncertainty that prevails before on-scale biophysical, biochemical and/or biological measurements become possible.
晶体学片段筛选为鉴定结晶蛋白的小分子配体提供了一种高效、有效的方法。由于其分子量低,此类命中物往往对其靶标具有低亲和力,通常无法量化,这使得验证命中物是否为靶标的真实溶液相配体以及确定用于进一步阐述的“最佳”命中物变得复杂。本文评估了应对这些挑战的方法。通过对最近一次 ATAD2 命中鉴定活动的回顾性分析,以及其他成功的片段筛选活动的例子,建议通过“三角测量”方法来验证和确定命中物优先级,该方法将多种可用的生化和生物物理技术的结果进行关联,以建立定性结构活性关系(SAR)。这种定性 SAR 实际上可能是在进行大规模生物物理、生化和/或生物学测量之前,在存在普遍不确定性的情况下,指导项目前进的唯一方法。